Physician profile
John C Wessner
NPI 1497723423
$12,003.50
in general payments reported to CMS, 2019-2025
42 companies · $1,347 in 2025
The $1,347 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,545 · 2020: $1,696 · 2021: $2,071 · 2022: $2,098 · 2023: $1,835 · 2024: $1,412 · 2025: $1,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,593 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,592.69 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,408.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,260.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $1,182.68 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $919.20 | 2019-2025 | |
| Amgen INC. | $731.71 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $702.34 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $625.24 | 2019-2023 | |
| Glaxosmithkline, LLC. | $613.23 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $579.05 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $564.56 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $528.75 | 2019-2024 | Xarelto, Spravato |
| E.R. Squibb & Sons, L.L.C. | $363.70 | 2019-2025 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.82 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $319.68 | 2021-2024 | Qulipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $284.16 | 2019-2024 | Xifaxan, Trulance |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $206.57 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $157.00 | 2021-2025 | Rexulti |
| Allergan, INC. | $102.94 | 2019-2020 | |
| Nevro Corp. | $101.70 | 2022-2024 | Senza |
| Phathom Pharmaceuticals, INC. | $97.25 | 2024-2025 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $88.63 | 2019-2025 | Zoryve, Livalo, Seglentis |
| Medtronic Vascular, INC. | $81.49 | 2019 | |
| Scilex Pharmaceuticals INC. | $69.28 | 2021-2024 | Ztlido |
| Exact Sciences Corporation | $68.84 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Esperion Therapeutics, INC. | $61.35 | 2024-2025 | Nexletol |
| Corcept Therapeutics | $59.13 | 2022 | |
| Eisai INC. | $55.77 | 2020-2021 | |
| Seqirus USA INC | $50.93 | 2025 | Flucelvax |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.79 | 2024-2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $42.64 | 2023-2024 | Keveyis, Gvoke Hypopen |
| Lundbeck LLC | $38.37 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $34.87 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $34.47 | 2021-2025 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $33.50 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $29.79 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.75 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.47 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.31 | 2024 | Unithroid |
| Arbor Pharmaceuticals, INC. | $14.71 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.66 | 2022 | |
| Almatica Pharma LLC | $11.15 | 2021 | |
| Axsome Therapeutics, INC. | $10.68 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wessner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.